{"id":34773,"date":"2025-06-05T17:52:51","date_gmt":"2025-06-05T09:52:51","guid":{"rendered":"https:\/\/flcube.com\/?p=34773"},"modified":"2025-06-05T17:52:53","modified_gmt":"2025-06-05T09:52:53","slug":"nmpa-accepts-nda-for-innovent-and-hutchmeds-tyvyt-and-elunate-combination","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34773","title":{"rendered":"NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination"},"content":{"rendered":"\n

Chinese companies Innovent Biologics, Inc. (HKG: 1801<\/a>) and HutchMed (China) Ltd (NASDAQ: HCM<\/a>, HKG: 0013<\/a>) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.<\/p>\n\n\n\n

Clinical Trial Basis<\/strong>
The NDA filing is based on results from the FRUSICA-2 study. The study demonstrated that the combination therapy met the primary endpoint of progression-free survival (PFS) compared to axitinib or everolimus alone. Secondary endpoints also showed improvements in objective response rate (ORR) and duration of response (DoR). The safety profile of the combination was manageable, with no new safety signals observed.<\/p>\n\n\n\n

Previous Approval<\/strong>
In December 2024, the sintilimab\/fruquintinib combination was approved for the treatment of advanced endometrial cancer.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)…<\/p>\n","protected":false},"author":1,"featured_media":34774,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,1105,910,285,198,38,1104,18,33],"class_list":["post-34773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-0013","tag-hkg-1801","tag-hutchmed","tag-innovent-biologics","tag-market-approval-filings","tag-nasdaq-hcm","tag-pd-1-l1","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"\nNMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34773\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination\" \/>\n<meta property=\"og:description\" content=\"Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34773\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T09:52:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-05T09:52:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination\",\"datePublished\":\"2025-06-05T09:52:51+00:00\",\"dateModified\":\"2025-06-05T09:52:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0505.webp\",\"keywords\":[\"Cancer\",\"HKG: 0013\",\"HKG: 1801\",\"HutchMed\",\"Innovent Biologics\",\"Market approval filings\",\"NASDAQ: HCM\",\"PD-1\\\/L1\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34773#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34773\",\"name\":\"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0505.webp\",\"datePublished\":\"2025-06-05T09:52:51+00:00\",\"dateModified\":\"2025-06-05T09:52:53+00:00\",\"description\":\"Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34773\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0505.webp\",\"width\":1080,\"height\":608,\"caption\":\"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34773#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination - Insight, China's Pharmaceutical Industry","description":"Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34773","og_locale":"en_US","og_type":"article","og_title":"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination","og_description":"Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.","og_url":"https:\/\/flcube.com\/?p=34773","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-05T09:52:51+00:00","article_modified_time":"2025-06-05T09:52:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34773#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34773"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination","datePublished":"2025-06-05T09:52:51+00:00","dateModified":"2025-06-05T09:52:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34773"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34773#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp","keywords":["Cancer","HKG: 0013","HKG: 1801","HutchMed","Innovent Biologics","Market approval filings","NASDAQ: HCM","PD-1\/L1","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34773#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34773","url":"https:\/\/flcube.com\/?p=34773","name":"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34773#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34773#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp","datePublished":"2025-06-05T09:52:51+00:00","dateModified":"2025-06-05T09:52:53+00:00","description":"Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for the combination of Tyvyt (sintilimab) and Elunate (fruquintinib) has been accepted by China\u2019s National Medical Products Administration (NMPA). The therapy targets patients with locally advanced or metastatic renal cell carcinoma (RCC) who have previously failed tyrosine kinase inhibitor (TKI) therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34773#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34773"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34773#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp","width":1080,"height":608,"caption":"NMPA Accepts NDA for Innovent and HutchMed's Tyvyt and Elunate Combination"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34773#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34773"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34773\/revisions"}],"predecessor-version":[{"id":34775,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34773\/revisions\/34775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34774"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}